David Guyer, MD - Partner
Focus: Biotechnology
Summary:
David Guyer joined SVLS in 2006. He serves on the Boards of portfolio
companies Link Medicine, Lux Biosciences, NeoVista, Neurotech
and Ophthotech.
Prior Experience:
David co-founded and served as CEO and director for six years
at Eyetech Pharmaceuticals (former Ticker 'EYET') , Inc. a biopharmaceutical
company that specialized in the development and commercialization
of novel therapeutics to treat diseases of the eye. He led the
firm through private financing rounds totaling approximately
$170 million, a $157 million initial public offering and a secondary
financing. The company also developed and gained FDA approval
for Macugen, a product to treat macular degeneration, which Eyetech
partnered with Pfizer in a deal valued at over $750 million.
OSI Pharmaceuticals subsequently acquired Eyetech in a deal valued
at $935 million. Prior to founding Eyetech, Dr. Guyer was professor
and chairman of the department of ophthalmology at the NYU School
of Medicine.
Qualifications:
David received a BSc from Yale College and an MD from Johns
Hopkins Medical School.
